Merck reported adjusted EPS of $0.03, beating the estimated loss of $0.11. Revenue was $14.63 billion vs the $14.50 billion estimate. The pharmaceutical giant reported a $1.23 billion net quarterly loss due to charges from an October deal with Japanese drugmaker Daiichi Sankyo to co-develop three promising cancer treatments. Merck is making strides to offset the anticipated revenue decline from Keytruda's 2028 patent expiration, securing new deals and preparing for key drug launches.